Glycosyl-modified fusion protein, nucleic acid molecule, expression vector, host cell and application thereof
CA3309581A1Pending Publication Date: 2026-08-05CHIMIGEN BIOMEDICAL (CHENGDU) CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CA3309581
- Authority / Receiving Office
- CA · CA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-20
- Filing Date
- 2025-08-28
- Publication Date
- 2026-08-05
Abstract
The present application provides a glycosyl-modified fusion protein, a nucleic acid molecule, an expression vector, a host cell and applications thereof. A first aspect of the present application provides a glycosyl-modified fusion protein, including a murine Fc variant and a hepatitis B virus antigen, where the murine Fc variant is obtained by subjecting a murine Fc fragment to amino acid mutation and non-mammalian glycosylation modification; the murine Fc variant includes at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330, and glutamic acid at position 332; the glycosylation modification does not include sialic acid modification; the numbering of position is performed according to EU numbering system. The fusion protein is capable of binding to and activating DCs and promoting proliferation and activation of specific T cells.
Need to check novelty before this filing date? Find Prior Art